长期低剂量PDE5抑制剂治疗勃起功能障碍的新进展  

Long-term administration of low-dose phosphodiesterase type 5 inhibitors for erectile dysfunction: An update

作　　者：姜睿[1] 

机构地区：[1]泸州医学院附属医院泌尿外科,四川泸州646000

出　　处：《中华男科学杂志》2013年第3期195-198,共4页National Journal of Andrology

基　　金：国家自然科学基金(81070486);四川省杰出青年学术技术带头人培育基金(2010JQ0040)~~

摘　　要：勃起功能障碍(ED)是一类常见的疾病,严重影响患者及其伴侣的生活质量,5型磷酸二酯酶(PDE5)抑制剂是治疗ED的首选药物,新近发现给予ED患者长期低剂量PDE5抑制剂同样安全有效,使得性生活更自然更方便,并为难治性ED患者提供了一种新的治疗选择,其机制在于改善阴茎血管内皮细胞的功能以及增加和(或)维持平滑肌细胞数量促进ED改善,但该方法是否能够使患者在服药结束后维持勃起功能依然是当前研究的热点。Erectile dysfunction （ED） is a common disorder that affects the quality of life of both men and their partners. The phosphodiesterase type 5 inhibitor is the first-line drug for ED. Recent researches found that long-term administration of low-dose phosphodiesterase type 5 inhibitors to be a safe and effective therapy for ED, as well as for couples who may prefer more convenience and spontaneity in their sexual activities. Besides, it provides a new therapeutic option for refractory ED. Its action mechanism mainly in- volves the improvement of the endothelial function of penile vessels and/or maintenance of the function and number of smooth muscle cells. However, whether this therapy can maintain the improved erection function after drug withdrawal needs further studies.

关 键 词：勃起功能障碍 5型磷酸二酯酶抑制剂 治疗 

分 类 号：R698.1[医药卫生—泌尿科学]